Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
Who is this study for? Patients with Meniere's disease
What treatments are being studied? Montelukast
Status: Active_not_recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
The purpose of this study is to evaluate a previously FDA-approved medication that is known to help with allergy symptoms to see if it can decrease symptoms in patients with Meniere's Disease.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adults 18 years of age or older
• Must meet all AAO-HNS 2020 criteria for definite or probable Meniere's Disease
• Must have a skin test positive for allergy
• Is already a candidate for treatment with montelukast for allergic rhinitis/failed first line over-the-counter allergy treatments
Locations
United States
California
House Ear Clinic
Los Angeles
House Institute Foundation
Los Angeles
Time Frame
Start Date: 2021-06-07
Completion Date: 2025-12-31
Participants
Target number of participants: 39
Treatments
Experimental: Montelukast 10 mg
Subjects will be instructed to take one pill at night for 90 days
Placebo_comparator: Placebo
Subjects will be instructed to take one pill at night for 90 days
Authors
Related Therapeutic Areas
Sponsors
Leads: House Ear Institute
Collaborators: Cures Within Reach